Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.
about
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CClinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosisKASL clinical practice guidelines: management of hepatitis CTreatment strategies for chronic hepatitis C prior to and following liver transplantationRisk Factors for the Development of Hepatocellular Carcinoma in ThailandEra of direct acting antivirals in chronic hepatitis C: Who will benefit?Impact of new treatment options for hepatitis C virus infection in liver transplantationHepatitis C: Treatment of difficult to treat patientsHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?Hepatitis C cirrhosis: New perspectives for diagnosis and treatmentThyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspectiveThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updatePotential role of thymosin Beta 4 in liver fibrosisLiver fibrosis: mechanisms of immune-mediated liver injuryThe natural history of hepatitis C virus (HCV) infection.Clinical guidelines on the management of hepatitis CViruses and human cancerHepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis CHepatitis C: a clinical reviewTargeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patientsCost-effectiveness of Telaprevir combination therapy for chronic hepatitis CDiagnosis, management, and treatment of hepatitis C: an updateCourse and outcome of hepatitis CGut Microbiota and Complications of Liver Disease.Global epidemiology and burden of HCV infection and HCV-related disease.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisTreatment of hepatitis C. The 2002 French consensus.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function.Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study.Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers.Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study.Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients.
P2860
Q24201588-0ACB3D62-2EFF-4920-B4DA-EB8529023037Q24791398-1710E028-AD8D-43B9-88DE-EDF629707DDFQ26744390-5F4CB001-4668-492A-ADCD-EF5D4C002F19Q26752471-F2E6FF45-4A09-49CE-8AF3-3B11DFE2BF20Q26771244-0AA57A4A-AD67-495B-B8D2-0D554D9AF0D6Q26775650-76F6F692-6780-4E89-99B6-3DAF5AE39617Q26777506-6230E5AF-385F-4833-B2DA-337B8D3A2CC4Q26782017-DCF1DECC-C930-4578-92D7-C7207E702C82Q26798465-02331F29-4E08-420E-A6F9-859A911274A1Q26798469-128DC6C7-09E5-4E4F-9416-5F8328A51774Q26799924-7347BF5A-8ADD-42F4-859A-AB903EC7769AQ26827517-23A34A2A-6BAA-4C3D-B357-FABBADEB1CF2Q27003050-7BBD6BEB-3DF7-48C2-8DD8-C240DC90C6D3Q27003833-3392643A-457B-407F-8D3E-7C909480D191Q27027766-0300B4D3-25D1-40E8-9A9C-EDEC944E8CB1Q27473116-BF1D9941-0FB3-406F-AEF6-5D0DA93D0E49Q27477946-46695962-7804-47DD-861E-D3ACA5E16712Q27481175-C836F35F-8A7A-4A0D-B1B0-3A9B3BAEB29CQ27486537-353C0681-32CA-4486-B737-4CC34F5469B6Q27490788-75821FFE-1632-4029-8809-C09F14DF41BAQ28085015-ABA67A06-73E7-4D69-B0E1-0C9F9843E612Q28540562-C71B5883-3F19-46C4-9F59-89DE2B5DF0BAQ29619682-EAA58C2B-F384-41E4-A46F-4FA1171293A5Q29620057-1FB379C7-33B5-4BCE-8439-7A11A5B62F11Q30236024-636817D0-0182-49B8-901C-E9A4FA669AFDQ30240220-ED2949DF-4A23-459E-885F-CEFEB99EBDF6Q30250088-ED1F91BD-E388-40B3-9573-77060F836FF3Q30444892-A2B136AB-C535-4752-86EB-7541ED616C64Q30479629-E685B613-A50B-48D8-A70B-62AB490A9D40Q31157282-FFFC368D-94FD-490A-9C63-1BBAF4B5AD94Q33195269-E3C7B41B-75A4-479C-80F1-5BF245E044BEQ33344056-EC307F78-763C-4623-8587-96E713E2D744Q33368159-370A967E-A1F4-4216-850B-0D5A9AE2AE8AQ33391761-190590A8-645C-4C4F-94CE-29DFE99D9C3AQ33392749-4E6430B1-A1EF-4978-AB47-0DB37A7B0FEFQ33406835-241DE7AE-5BB2-41EF-90F8-89AD0023AB97Q33516543-69FB2B7C-B05D-4E55-8D23-8CA04F78DF19Q33594968-537DF2BF-AFCF-4EF6-ABC2-969B60BB3A1EQ33618516-C88EE2D9-AD8D-4EA9-9839-4AD55F6AF568Q33652027-DD0E6B7A-7B22-4247-AED3-97AF83D94B21
P2860
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Morbidity and mortality in com ...... llow-up study of 384 patients.
@ast
Morbidity and mortality in com ...... llow-up study of 384 patients.
@en
Morbidity and mortality in com ...... llow-up study of 384 patients.
@nl
type
label
Morbidity and mortality in com ...... llow-up study of 384 patients.
@ast
Morbidity and mortality in com ...... llow-up study of 384 patients.
@en
Morbidity and mortality in com ...... llow-up study of 384 patients.
@nl
prefLabel
Morbidity and mortality in com ...... llow-up study of 384 patients.
@ast
Morbidity and mortality in com ...... llow-up study of 384 patients.
@en
Morbidity and mortality in com ...... llow-up study of 384 patients.
@nl
P2093
P1433
P1476
Morbidity and mortality in com ...... llow-up study of 384 patients.
@en
P2093
Brouwer JT
Fattovich G
P304
P356
10.1053/GAST.1997.V112.PM9024300
P407
P577
1997-02-01T00:00:00Z